is tirzepatide still in shortage The Over: Here's What You Need to Know GLP-1 No Longer on FDA's

By Amina Niasse NEW YORK, June 2 (Reuters) - Health insurer Cigna will stop covering GLP-1 weight-loss drugs including Novo Nordisk's Wegovy and Eli Lilly's Zepbound in its employee health plan effective July 1, according to materials viewed by Reuters on Tuesday

Three biological replicates were carried out in this study

For researchers concerned about tirzepatide expiration , a 12-month BUD represents a meaningful advantage over shorter-dated alternatives

The Bottom Line: Compared with other GLP-1 RAs, Ozempic is a strong A1c reducer with the added benefits of moderate weight loss and possible cardiovascular protection

1 CPD point = 1 hour of learning